Ideaya Biosciences, Genentech launch Phase 1 combo trial in KRAS G12D PDAC
Ideaya Biosciences (IDYA) announces a clinical collaboration with Genentech to sponsor a jointly governed trial and plan a Phase 1 combination cohort with Roche’s rg6505 in mtap-deleted, KRAS G12D mutant pancreatic cancer in 2H 2026.
IDYA Ideaya Biosciences announces clinical collaboration with genentech in mtap-deleted kras g12d-mutant pancreatic cancer Ideaya Biosciences, - genentech to sponsor clinical trial with Joint governance - Plans to initiate a phase 1 combination cohort with Roche's rg6505 in mtap-deleted, ras-mutant pdac in 2h 2026 - Co and genentech retain all commercial rights to their compounds - To supply ide892 for clinical trial